Today: 9 June 2026
Lattice Semiconductor stock price drops into the weekend as chip slump deepens ahead of Feb. 10 call
1 February 2026
1 min read

Lattice Semiconductor stock price drops into the weekend as chip slump deepens ahead of Feb. 10 call

New York, Jan 31, 2026, 21:36 (EST) — Market closed.

  • Shares of Lattice Semiconductor fell 3.35% on Friday, ending the day at $80.52.
  • Chip stocks took a broad hit, dragging the iShares Semiconductor ETF down over 4% on the day.
  • Investors are eyeing the U.S. jobs report due Feb. 6 and Lattice’s earnings call scheduled for Feb. 10 as the next potential catalysts.

Lattice Semiconductor shares dropped 3.35% on Friday, closing at $80.52 on the Nasdaq amid a pullback in chip stocks.

As U.S. markets remain closed for the weekend, all eyes shift to Lattice’s Feb. 10 conference call covering fourth-quarter and full-year 2025 results, along with its business outlook. CEO Ford Tamer and CFO Lorenzo Flores will lead the call.

The decline hit more than a single stock. On Jan. 30, the iShares Semiconductor ETF saw its NAV fall 4.15% in a single day.

Shares of other chipmakers linked to industrial and embedded markets also declined Friday. Microchip Technology slid 4.33%, while NXP Semiconductors dropped 3.15%, according to data.

Wall Street’s major indexes slipped on Friday, pressured by President Donald Trump’s nomination of Kevin Warsh to replace Jerome Powell. Investors also wrestled with ongoing concerns over inflation and corporate earnings. “Markets are calibrating to Trump’s pick of Kevin Warsh … and the outlook for monetary policy,” noted Michael Hans of Citizens Wealth. Reuters

Rate expectations continue to drive movements in many growth stocks. Federal Reserve Vice Chair for Supervision Michelle Bowman indicated she still sees rate cuts coming this year, even after the Fed paused its policy rate at 3.50% to 3.75%. “The labor market is fragile,” Bowman noted. Reuters

Lattice produces low-power programmable chips called FPGAs — field-programmable gate arrays — which find applications in communications equipment, industrial machinery, and consumer electronics. Demand can shift rapidly if customers delay deployments or clear out existing stock.

Next week will see a flood of earnings reports, with a spotlight on capital spending—capex—tied to AI infrastructure. “It did confirm that capex spending on building out AI infrastructure will not see any letup,” said Sid Vaidya of TD Wealth. Advanced Micro Devices is among the companies set to report earnings. Reuters

The next move in Lattice could hinge on its guidance. If the company signals caution or points to weaker orders in industrial and communications sectors, the stock might drift lower with its peers—especially if interest rates climb or risk appetite wanes.

Traders have their eyes set on a specific date: the U.S. Employment Situation report for January arrives Feb. 6 at 8:30 a.m. ET. Then, Lattice is scheduled to hold its results call on Feb. 10.

Stock Market Today

  • S&P 500 Rallies on Chipmaker Gains; Crude Oil Prices Retreat After Iran-Israel Ceasefire Signal
    June 9, 2026, 9:24 AM EDT. The S&P 500 gained +0.30% on Monday, driven by renewed investor interest in artificial intelligence boosting chipmakers. Nasdaq 100 rose +1.58%, while the Dow slipped -0.16%, dragged lower by Apple's -1% drop amid lukewarm AI platform feedback. Crude oil prices surged over +4% initially due to Iran-Israel tensions but retreated after Iran signaled an end to its current military operation. The market discounts a low 3% chance of a +25 basis point rate hike by the Federal Reserve on June 16-17. Treasury yields climbed, with 10-year notes reaching a two-week high of 4.58%, pressured by strong US jobs data and heavy upcoming Treasury auctions. Overseas markets closed mixed, with China's Shanghai Composite down -1.70% and Japan's Nikkei falling -3.85%.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Longsys Electronics stock set for Monday test after profit jump forecast and a sharp Friday drop
Previous Story

Longsys Electronics stock set for Monday test after profit jump forecast and a sharp Friday drop

SSE share price flat at 2,422p as a key trading update looms this week
Next Story

SSE share price flat at 2,422p as a key trading update looms this week

Go toTop